New Risk • May 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (33% average weekly change). Earnings have declined by 28% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (CN¥496.7m market cap, or US$68.9m). New Risk • May 07
New major risk - Revenue and earnings growth Earnings have declined by 28% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (33% average weekly change). Earnings have declined by 28% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (CN¥385.1m market cap, or US$53.3m). New Risk • Apr 28
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: CN¥362.7m (US$49.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (34% average weekly change). Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (CN¥362.7m market cap, or US$49.7m). Board Change • Apr 28
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 5 highly experienced directors. CFO, Deputy GM & Non-Independent Director Tong Ning Luo was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Announcement • Mar 31
Hainan Poly Pharm. Co., Ltd to Report Q1, 2025 Results on Apr 29, 2025 Hainan Poly Pharm. Co., Ltd announced that they will report Q1, 2025 results on Apr 29, 2025 Announcement • Dec 31
Hainan Poly Pharm. Co., Ltd to Report Fiscal Year 2024 Results on Apr 21, 2025 Hainan Poly Pharm. Co., Ltd announced that they will report fiscal year 2024 results on Apr 21, 2025 Reported Earnings • Oct 28
Third quarter 2024 earnings released: CN¥0.089 loss per share (vs CN¥0.31 profit in 3Q 2023) Third quarter 2024 results: CN¥0.089 loss per share (down from CN¥0.31 profit in 3Q 2023). Revenue: CN¥187.8m (down 64% from 3Q 2023). Net loss: CN¥41.5m (down 131% from profit in 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance. Announcement • Sep 30
Hainan Poly Pharm. Co., Ltd to Report Q3, 2024 Results on Oct 28, 2024 Hainan Poly Pharm. Co., Ltd announced that they will report Q3, 2024 results on Oct 28, 2024 Reported Earnings • Aug 29
Second quarter 2024 earnings released: CN¥0.29 loss per share (vs CN¥0.30 profit in 2Q 2023) Second quarter 2024 results: CN¥0.29 loss per share (down from CN¥0.30 profit in 2Q 2023). Revenue: CN¥131.1m (down 72% from 2Q 2023). Net loss: CN¥123.5m (down 194% from profit in 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 26 percentage points per year, which is a significant difference in performance. Valuation Update With 7 Day Price Move • Aug 21
Investor sentiment improves as stock rises 30% After last week's 30% share price gain to CN¥11.13, the stock trades at a trailing P/E ratio of 57.9x. Average trailing P/E is 27x in the Pharmaceuticals industry in China. Total loss to shareholders of 74% over the past three years. Announcement • Aug 05
Hainan Poly Pharm. Co., Ltd, Annual General Meeting, Aug 23, 2024 Hainan Poly Pharm. Co., Ltd, Annual General Meeting, Aug 23, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Haikou, Hainan China Valuation Update With 7 Day Price Move • Aug 02
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to CN¥9.15, the stock trades at a trailing P/E ratio of 47.6x. Average trailing P/E is 27x in the Pharmaceuticals industry in China. Total loss to shareholders of 80% over the past three years. Valuation Update With 7 Day Price Move • Jul 12
Investor sentiment deteriorates as stock falls 36% After last week's 36% share price decline to CN¥7.88, the stock trades at a trailing P/E ratio of 41x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total loss to shareholders of 83% over the past three years. Reported Earnings • Jul 08
First quarter 2024 earnings released: EPS: CN¥0.15 (vs CN¥0.32 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.15 (down from CN¥0.32 in 1Q 2023). Revenue: CN¥306.3m (down 18% from 1Q 2023). Net income: CN¥66.7m (down 52% from 1Q 2023). Profit margin: 22% (down from 37% in 1Q 2023). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 34% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has fallen by 41% per year, which means it is performing significantly worse than earnings. Board Change • Jul 08
High number of new directors There are 5 new directors who have joined the board in the last 3 years. CFO, Deputy GM & Non-Independent Director Tong Ning Luo was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Jun 29
Hainan Poly Pharm. Co., Ltd to Report First Half, 2024 Results on Aug 29, 2024 Hainan Poly Pharm. Co., Ltd announced that they will report first half, 2024 results on Aug 29, 2024 New Risk • May 11
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (18% operating cash flow to total debt). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Large one-off items impacting financial results. Shareholders have been diluted in the past year (3.2% increase in shares outstanding). Valuation Update With 7 Day Price Move • May 03
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥12.35, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total loss to shareholders of 74% over the past three years. Valuation Update With 7 Day Price Move • Apr 17
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥14.86, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total loss to shareholders of 68% over the past three years. Announcement • Mar 30
Hainan Poly Pharm. Co., Ltd to Report Q1, 2024 Results on Apr 25, 2024 Hainan Poly Pharm. Co., Ltd announced that they will report Q1, 2024 results on Apr 25, 2024 Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥16.20, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 16x in the Pharmaceuticals industry in China. Total loss to shareholders of 64% over the past three years. Announcement • Dec 29
Hainan Poly Pharm. Co., Ltd to Report Fiscal Year 2023 Results on Apr 20, 2024 Hainan Poly Pharm. Co., Ltd announced that they will report fiscal year 2023 results on Apr 20, 2024 New Risk • Dec 04
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (3.2% increase in shares outstanding). Valuation Update With 7 Day Price Move • Oct 31
Investor sentiment improves as stock rises 56% After last week's 56% share price gain to CN¥31.68, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total loss to shareholders of 26% over the past three years. New Risk • Oct 29
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 27% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (9.3% average weekly change). Minor Risk Large one-off items impacting financial results. New Risk • Oct 27
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (9.3% average weekly change). New Risk • Oct 25
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 18% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (18% operating cash flow to total debt). Minor Risk Share price has been volatile over the past 3 months (7.3% average weekly change). Reported Earnings • Oct 25
Third quarter 2023 earnings released: EPS: CN¥0.31 (vs CN¥0.38 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.31 (down from CN¥0.38 in 3Q 2022). Revenue: CN¥518.2m (down 9.9% from 3Q 2022). Net income: CN¥134.4m (down 20% from 3Q 2022). Profit margin: 26% (down from 29% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings. Announcement • Sep 30
Hainan Poly Pharm. Co., Ltd to Report Q3, 2023 Results on Oct 25, 2023 Hainan Poly Pharm. Co., Ltd announced that they will report Q3, 2023 results on Oct 25, 2023 Reported Earnings • Aug 25
Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.29 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.30 (up from CN¥0.29 in 2Q 2022). Revenue: CN¥460.9m (up 7.8% from 2Q 2022). Net income: CN¥131.5m (up 4.5% from 2Q 2022). Profit margin: 28% (in line with 2Q 2022). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Aug 14
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥22.65, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total loss to shareholders of 45% over the past three years. Announcement • Jul 12
Hainan Poly Pharm. Co., Ltd Announces Dividend Implementation of Cash Dividend for 2022, Payable on 18 July 2023 Hainan Poly Pharm. Co. Ltd. announced 2022 final profit distribution plan to be implemented (A shares) cash dividend per 10 shares (tax included) of CNY 0.78721100. Record date: 17 July 2023; Ex-date: 18 July 2023; Payment date: 18 July 2023. Reported Earnings • Apr 26
First quarter 2023 earnings released: EPS: CN¥0.32 (vs CN¥0.37 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.32 (down from CN¥0.37 in 1Q 2022). Revenue: CN¥373.2m (up 1.4% from 1Q 2022). Net income: CN¥138.4m (down 14% from 1Q 2022). Profit margin: 37% (down from 44% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Apr 18
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥24.14, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 24x in the Pharmaceuticals industry in China. Total loss to shareholders of 48% over the past three years. Board Change • Nov 16
High number of new directors There are 5 new directors who have joined the board in the last 3 years. CFO, Deputy GM & Non-Independent Director Tong Ning Luo was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 25
Third quarter 2022 earnings released: EPS: CN¥0.38 (vs CN¥0.37 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.38 (up from CN¥0.37 in 3Q 2021). Revenue: CN¥575.1m (up 12% from 3Q 2021). Net income: CN¥167.9m (up 1.7% from 3Q 2021). Profit margin: 29% (down from 32% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥27.67, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 20x in the Pharmaceuticals industry in China. Total loss to shareholders of 30% over the past three years. Reported Earnings • Aug 31
Second quarter 2022 earnings released: EPS: CN¥0.29 (vs CN¥0.29 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.29 (up from CN¥0.29 in 2Q 2021). Revenue: CN¥427.7m (up 22% from 2Q 2021). Net income: CN¥125.8m (up 21% from 2Q 2021). Profit margin: 29% (in line with 2Q 2021). Over the next year, revenue is forecast to grow 25%, compared to a 21% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Announcement • Jul 07
Hainan Poly Pharm. Co., Ltd Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on July 13, 2022 Hainan Poly Pharm. Co. Ltd. announced 2021 final profit distribution plan to be implemented (A shares), Payable on July 13, 2022. The company announced Cash dividend/10 shares (tax included) of CNY 1.91803000. The ex-date is July 13, 2022 and record date is July 12, 2022. Valuation Update With 7 Day Price Move • Jun 24
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥33.25, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 20x in the Pharmaceuticals industry in China. Total loss to shareholders of 11% over the past three years. Announcement • May 19
Hainan Poly Pharm. Co., Ltd Approves Cash Dividend for the Year 2021 Hainan Poly Pharm. Co. Ltd. announced that at its Annual General Meeting held on 17 May 2022, approved cash dividend/10 shares (tax included) of CNY 1.91000000 for the year 2021. Announcement • Apr 27
Hainan Poly Pharm. Co.,Ltd Proposes Profit Distribution for 2021 Hainan Poly Pharm. Co.,Ltd announced profit distribution proposal for 2021 as final Cash dividend/10 shares (tax included): CNY 1.91000000. Board Change • Apr 27
High number of new directors There are 5 new directors who have joined the board in the last 3 years. CFO & Non-Independent Director Tong Ning Luo was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 15
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: CN¥0.94 (vs CN¥0.94 in FY 2020). Revenue: CN¥1.51b (up 27% from FY 2020). Net income: CN¥410.9m (flat on FY 2020). Profit margin: 27% (down from 34% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 11%. Earnings per share (EPS) also missed analyst estimates by 26%. Over the next year, revenue is forecast to grow 58%, compared to a 27% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Apr 13
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥36.30, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 22x in the Pharmaceuticals industry in China. Total returns to shareholders of 17% over the past three years. Announcement • Feb 11
Hainan Poly Pharm. Co., Ltd. (SZSE:300630) announces an Equity Buyback for CNY 10 million worth of its shares. Hainan Poly Pharm. Co., Ltd. (SZSE:300630) announces a share repurchase program. Under the program, the company will repurchase up to CNY 10 million worth of shares. The shares will be repurchased at a maximum price of CNY 76.76 per share. The program is valid for 6 months. Reported Earnings • Oct 26
Third quarter 2021 earnings released: EPS CN¥0.37 (vs CN¥0.29 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: CN¥513.6m (up 35% from 3Q 2020). Net income: CN¥165.0m (up 31% from 3Q 2020). Profit margin: 32% (down from 33% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 34% per year whereas the company’s share price has increased by 30% per year. Valuation Update With 7 Day Price Move • Sep 17
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥45.70, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 74% over the past three years. Reported Earnings • Aug 10
Second quarter 2021 earnings released: EPS CN¥0.29 (vs CN¥0.18 in 2Q 2020) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: CN¥349.7m (up 52% from 2Q 2020). Net income: CN¥103.9m (up 33% from 2Q 2020). Profit margin: 30% (down from 34% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Announcement • May 21
Hainan Poly Pharm. Co., Ltd. Approves Profit Distribution Proposal for 2020 Hainan Poly Pharm. Co., Ltd., at its AGM held on May 18, 2021, approved profit distribution proposal of CNY 1.87 per 10 shares (tax included) for the year 2020. Announcement • Apr 27
Hainan Poly Pharm. Co., Ltd. Announces Final Dividend for the Year 2020 Hainan Poly Pharm. Co., Ltd. announced final cash dividend CNY 1.87 per 10 shares (tax included) for the year 2020. Reported Earnings • Apr 25
Full year 2020 earnings released: EPS CN¥0.94 (vs CN¥0.72 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥1.19b (up 25% from FY 2019). Net income: CN¥407.5m (up 35% from FY 2019). Profit margin: 34% (up from 32% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Feb 22
New 90-day high: CN¥49.28 The company is up 22% from its price of CN¥40.55 on 24 November 2020. The Chinese market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥2.77 per share. Is New 90 Day High Low • Jan 22
New 90-day high: CN¥47.61 The company is up 10.0% from its price of CN¥43.16 on 23 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥2.77 per share. Is New 90 Day High Low • Dec 22
New 90-day low: CN¥38.94 The company is down 6.0% from its price of CN¥41.26 on 23 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥2.77 per share. Reported Earnings • Oct 31
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥380.1m, up 43% from the prior year. Total revenue was CN¥1.12b over the last 12 months, up 35% from the prior year. Valuation Update With 7 Day Price Move • Oct 12
Market bids up stock over the past week After last week's 18% share price gain to CN¥46.98, the stock is trading at a trailing P/E ratio of 58.6x, up from the previous P/E ratio of 49.6x. This compares to an average P/E of 38x in the Pharmaceuticals industry in China. Total returns to shareholders over the past three years are 154%. Is New 90 Day High Low • Sep 24
New 90-day low: CN¥40.41 The company is down 13% from its price of CN¥46.54 on 24 June 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥2.38 per share. Announcement • Aug 11
Hainan Poly Pharm. Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020 Hainan Poly Pharm. Co., Ltd. announced that they will report first half, 2020 results on Aug 27, 2020 Announcement • Jul 17
Hainan Poly Pharm. Co., Ltd. announced a financing transaction Hainan Poly Pharm. Co., Ltd. (SZSE:300630) announced a private placement to issue convertible corporate bonds on July 10, 2020. The transaction will include participation from non-specific parties. The transaction has been approved by the shareholders of the company at the 3rd Extraordinary General Meeting of 2020.